Zobrazeno 1 - 10
of 49
pro vyhledávání: '"karcinom bubrega"'
Autor:
Jukić, Klara
Cilj istraživanja: Cilj ovog istraživanja bio je usporediti učestalost karcinoma bubrega dijagnosticiranih bolesnicima prije i za vrijeme pandemije Covid-19. Ispitanici i metode: Ovo istraživanje obuhvatilo je 222 patohistološka nalaza s potvrdo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::745259c4dc060b00808b08ef0b91ec48
https://urn.nsk.hr/urn:nbn:hr:171:860100
https://urn.nsk.hr/urn:nbn:hr:171:860100
Autor:
Marić, Marjan, Stemberger Marić, Lorna, Kurelac, Ivan, Vince, Adriana, Kaštelan, Željko, Papić, Neven
Publikováno v:
Infektološki glasnik
Volume 42
Issue 1
Volume 42
Issue 1
Neurologic symptoms secondary to a paraneoplastic syndrome (PNS) may be the presenting manifestation of a previously undiagnosed cancer. This case highlights the potential complexity of the PNS associated with renal cell carcinoma, confusion and dela
Autor:
Matulić, Ante
Uvod: Karcinom bubrega je zbog visoke učestalosti i mortaliteta jedan od najznačajnijih tumora urogenitalnog sustava. Svrha rada: Svrha ovog rada je prikazati kliničke značajke karcinoma bubrega i usporediti ih u vremenskom razdoblju od 20 godina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::e0ef518ce1f42e96c7688b3af8d32a70
https://repository.medri.uniri.hr/islandora/object/medri:4642/datastream/PDF
https://repository.medri.uniri.hr/islandora/object/medri:4642/datastream/PDF
Autor:
Mičetić, Domagoj
Vitamin D je liposolubilan spoj čija je osnovna uloga održavanje homeostaze kalcijevih iona u organizmu. No, receptor vitamina D i enzim 1α-hidroksilaza prisutni su u mnogim tkivima što čini temelj pretpostavke, koja je in vitro i in vivo modeli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::b4645a802a966ea4cbef1a819eee2144
https://urn.nsk.hr/urn:nbn:hr:184:838315
https://urn.nsk.hr/urn:nbn:hr:184:838315
Autor:
Ljubičić, Iva
Bubreg je parni organ crvenkastosmeđe boje, prosječne duljine 10 cm, širine 5 cm i debljine 3 cm. Leži retroperitonealno u visini između dvanaestog prsnog i trećeg lumbalnog kralješka. Desni je niže pozicioniran radi anatomskog položaja jetr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4012::9d9ace679206eae42004b7e44d6f2e9f
https://repozitorij.unizd.hr/islandora/object/unizd:4938/datastream/PDF
https://repozitorij.unizd.hr/islandora/object/unizd:4938/datastream/PDF
Autor:
FRAN ČAKAR, TIHANA REGOVIĆ DŽOMBETA
Publikováno v:
Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske
Volume 74
Issue 1
Volume 74
Issue 1
Aim: Renal oncocytoma (RO) and chromophobe renal cell carcinoma (ChRCC) are epithelial neoplasms of the kidney with overlapping histologic features, making their differential diagnosis one of the pitfalls in renal pathology. The aim of this study was
Autor:
David Bonifačić, Daniel V. Šimac, Zlatko Kolić, Damir Grebić, Ana Marija Tomasić, Ana Gavranić
Publikováno v:
Medicina Fluminensis : Medicina Fluminensis
Volume 54
Issue 2
Volume 54
Issue 2
Aim: Renal cell carcinoma is one of the deadliest cancers, takes third place among malignant carcinomas of the genitourinary tract. This case report describes the rare case of a large fast-growing metastasis of renal cell cancer in an unusual locatio
Autor:
Jaković, Mario
Bubrezi su retroperitonealni organi čija je osnovna i funkcionalna jedinica nefron. Karcinom bubrega nastaje malignom preobrazbom stanica bubrežnih kanalića. Svjetlostanični, papilarni, kromofobni i karcinom sabirnih tubula su najčešći podtipo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0673629fbf27805f1a433d289af1d764
https://repository.medri.uniri.hr/islandora/object/medri:3333/datastream/PDF
https://repository.medri.uniri.hr/islandora/object/medri:3333/datastream/PDF
Autor:
Marić, Predrag
Publikováno v:
Универзитет у Крагујевцу
Cilj studije je poređenje dužine preživljavanja vezanog za tumor i ukupnog preživljavanja i stanja bubrežne funkcije, kao i definisanje razlika u incidenci intraoperativnih i postoperativnih komplikacija pacijenata kod kojih je urađena radikaln
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=nardusnacion::866a0ed140881970da6d8d3b62f8be7d
https://hdl.handle.net/21.15107/rcub_nardus_11723
https://hdl.handle.net/21.15107/rcub_nardus_11723
Publikováno v:
Libri Oncologici : Croatian Journal of Oncology
Volume 47
Issue 2-3
Volume 47
Issue 2-3
Forty two to 57% of patients with metastatic renal cell carcinoma (mRCC) receive the second-line therapy according to available data. In our analysis we wanted to determine the percentage of patients within intermediate/poor prognostic group mRCC who